Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 10/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 10/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.35 |
| ▸ | USP1 | O94782 | 1/20 | 0.35 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22987708 | 0.88 | NR1H2 (0.48) | NR1H2NR1H3ADORA3ADORA2AADORA1 | |
| SCHEMBL22987510 | 0.86 | NR1H2 (0.50) | NR1H2NR1H3ADORA3ADORA2AADORA1 | |
| SCHEMBL22987660 | 0.83 | POLB (0.48) | ADORA3ADORA2AADORA1 | |
| SCHEMBL22987508 | 0.83 | AHR (0.38) | PDPK1ADORA3EGLN2ADORA2AADORA1 | |
| SCHEMBL22987505 | 0.80 | NR1H2 (0.41) | NR1H2NR1H3NR1I2NR3C1AR | |
| SCHEMBL22987675 | 0.78 | EGFR (0.38) | NR1H2NR1H3ADORA3ADORA2A | |
| SCHEMBL29646424 | 0.78 | ADORA3 (0.38) | NR1H2NR1H3ADORA3ADORA2AADORA1 | |
| SCHEMBL22978982 | 0.78 | ADORA3 (0.38) | NR1H2NR1H3ADORA3ADORA2AADORA1 | |
| SCHEMBL22987611 | 0.78 | ADORA3 (0.38) | NR1H2NR1H3ADORA3ADORA2AADORA1 | |
| SCHEMBL22987578 | 0.78 | ADORA3 (0.53) | ADORA3ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| WO-2021028382-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | AHR, HRH4, HRH1 | PDPK1 1415/4885NR1H2 296/4885NR1H3 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.